Evaluation of Outcomes After Initiating Triple Antidiabetic Therapy with a GLP-1 RA in an Integrated Health Care System

Journal of Managed Care & Specialty Pharmacy
Susan M LeeRita L Hui

Abstract

Type 2 diabetes (T2D) is characterized by chronic hyper-glycemia and can lead to life-threatening complications if not treated. A stepwise and patient-centered approach is recommended when managing patients with T2D. Metformin is the preferred first-line agent, while sulfonylureas (SU) are often chosen as second-line agents. If a patient's hemoglobin A1c (A1c) goal is not achieved despite 3 months of treatment with dual therapy, then triple therapy is recommended. However, due to the lack of head-to-head trials for different triple antidiabetic regimens, the recommendations are unclear for selection of an optimal third-line agent. To evaluate the comparative effectiveness of a glucagon-like peptide-1 receptor agonist (GLP-1 RA) compared with a thiazolidinedione (TZD) or insulin as a third-line add-on therapy in patients who have not achieved A1c goals while receiving metformin and SU dual therapy in the real-world setting within an integrated health care system. This is a retrospective cohort study of adult patients with T2D who were not at goal A1c while on dual therapy with metformin and an SU and initiated triple antidiabetic therapy. The primary outcome was the proportion of patients who achieved goal A1c within 3-7 months ...Continue Reading

References

May 18, 2011·Annals of Internal Medicine·Jorge L GrossUNKNOWN Diabetes and Endocrinology Meta-analysis Group (DEMA)
May 22, 2013·Diabetes Care·David M NathanUNKNOWN GRADE Study Research Group
Jun 14, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN LEADER Trial Investigators
Jun 21, 2016·Diabetes Research and Clinical Practice·Crystal Man Ying LeeStephen Colagiuri
Dec 17, 2016·Diabetes Care·UNKNOWN American Diabetes Association
Jan 18, 2017·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Alan J GarberGuillermo E Umpierrez
Feb 9, 2017·Frontiers in Endocrinology·Arun ChaudhuryWasique Mirza
Feb 1, 2018·Clinical Diabetes : a Publication of the American Diabetes Association·UNKNOWN American Diabetes Association

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.